Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: The liver effect of orlistat as a weight control treatment in patients with nonalcoholic fatty liver disease (NAFLD) with obesity remains undetermined. This study quantified liver fat improvement by orlistat in a Chinese cohort with NAFLD accompanied by obesity, diagnosed by a lower body mass index threshold than that for White patients. Materials and methods: We conducted a parallel-group, open-label, 24-week, randomized clinical trial registered at the Chinese Clinical Trial Registry (ChiCTR-IPR-17012258). Obese participants with NAFLD were randomized 1:1.5 to the intervention group with orlistat or conventional care. Liver fat quantification was assessed by magnetic resonance imaging-based proton density fat fraction with Dixon sequence. Results: Overall, 170 ( n = 68, orlistat 120 mg three times/day and n = 102, conventional therapy) and 130 patients with NAFLD ( n = 56, orlistat and n = 74, conventional therapy) were included for intention-to-treat (ITT) and per-protocol (PP) analysis, respectively. Orlistat reduced liver fat content to a greater degree than conventional care [−5.45% versus −1.96%, p < 0.001 (ITT analysis) and −6.66% versus −2.68%, p < 0.001 (PP analysis)]. The 6-month rate of decrease in steatosis grades was higher in the orlistat group [45.6% versus 22.5% (ITT analysis), 57.4% versus 30.3% (PP analysis), both p < 0.001]. Multivariate logistic regression analysis identified orlistat treatment [odds ratio (OR) = 2.4; 95% confidence interval (CI) 1.1–5.6, p = 0.036] as an independent predictor of steatosis improvement. Among patients with orlistat therapy, weight loss (OR = 1.2, 95% CI 1.1–1.4, p = 0.040) and severe steatosis (OR = 6.7, 95% CI: 1.1–40.3, p = 0.03) remained predictive of steatosis improvement. Conclusions: Orlistat can effectively promote steatosis improvement and may serve as a treatment option for controlling NAFLD. Chinese Clinical Trial Registry identifier: ChiCTR-IPR-17012258
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470
Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., et al. (2014) · Diabetes · doi:10.2337/db13-1622 · Cited by 429
Standards of care for type 2 diabetes in China
Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D., Zhu, D., Chen, L., Chen, L., Guo, L., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2827 · Cited by 315
Gu, J., Liu, S., Du, S., Zhang, Q., Xiao, J., Dong, Q., & Xin, Y. (2019) · European Radiology · doi:10.1007/s00330-019-06072-4 · Cited by 276
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.024 · Cited by 208
Utzschneider, K. M., Bayer-Carter, J. L., Arbuckle, M. D., Tidwell, J. M., Richards, T. L., & Craft, S. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512002966 · Cited by 81
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Koutoukidis, D. A., Koshiaris, C., Henry, J. A., Noreik, M., Morris, E., Manoharan, I., Tudor, K., Bodenham, E., Dunnigan, A., Jebb, S. A., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154455 · Cited by 186
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Metadata
- Authors
- Ye, J., Wu, Y., Li, F., Wu, T., Shao, C., Lin, Y., Wang, W., Feng, S., & Zhong, B.
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 12
- Pages
- 1756284819879047-1756284819879047
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- OpenAlex
- W2976995479
- Cited by
- 51
- References
- 11
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. https://app.cochat.ai/papers/10.1177/1756284819879047
- The paper
- Ye, J., Wu, Y., Li, F., Wu, T., Shao, C., Lin, Y., Wang, W., Feng, S., & Zhong, B. (2019). Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756284819879047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.